Basic mechanisms of calcific aortic valve disease

Canadian Journal of Cardiology

Volumn 30, Issue 9, 2014, Pages 982-993

  Mathieu, Patrick ^a   Boulanger, Marie Chloé ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BONE MORPHOGENETIC PROTEIN 2; CYTOKINE; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; LIPID; LOW DENSITY LIPOPROTEIN; MATRIX PROTEIN; PHOSPHATE; SEROTONIN RECEPTOR; SIRTUIN; TRANSFORMING GROWTH FACTOR BETA; UNTRANSLATED RNA;

AGING; AORTA VALVE; AORTA VALVE DISEASE; BONE DEVELOPMENT; CALCIFIC AORTIC VALVE DISEASE; ENDOTHELIUM; FIBROSIS; HISTOPATHOLOGY; HUMAN; INFLAMMATION; MECHANICAL STRESS; MINERALIZATION; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION;

AGING; AORTIC VALVE; AORTIC VALVE STENOSIS; BONE MORPHOGENETIC PROTEIN 2; CALCINOSIS; ENDOTHELIUM; HUMANS; INFLAMMATION; INTERLEUKIN-6; LIPID METABOLISM; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; NUCLEOSIDES; NUCLEOTIDES; PHOSPHATES; PHOSPHOLIPASES A2; RECEPTORS, SEROTONIN; RENIN-ANGIOTENSIN SYSTEM; RNA, UNTRANSLATED; SIGNAL TRANSDUCTION; SIRTUINS; STRESS, MECHANICAL; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84906318824     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.03.029     Document Type: Review

References (93)

1. Rajamannan N.M., Evans F.J., Aikawa E., et al. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update. Circulation 2011, 124:1783-1791.
2. O'Brien K.D., Reichenbach D.D., Marcovina S.M., et al. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996, 16:523-532.
3. Sider K.L., Blaser M.C., Simmons C.A. Animal models of calcific aortic valve disease. Int J Inflam 2011, 2011:364310.
4. Teo K.K., Corsi D.J., Tam J.W., Dumesnil J.G., Chan K.L. Lipid lowering on progression of mild to moderate aortic stenosis: meta-analysis of the randomized placebo-controlled clinical trials on 2344 patients. Can J Cardiol 2011, 27:800-808.
5. Warren B.A., Yong J.L. Calcification of the aortic valve: its progression and grading. Pathology 1997, 29:360-368.
6. Cote C., Pibarot P., Despres J.P., et al. Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis. Heart 2008, 94:1175-1180.
7. Otto C.M., Kuusisto J., Reichenbach D.D., Gown A.M., O'Brien K.D. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994, 90:844-853.
8. Charest A., Pepin A., Shetty R., et al. Distribution of SPARC during neovascularisation of degenerative aortic stenosis. Heart 2006, 92:1844-1849.
9. Mazzone A., Epistolato M.C., De Caterina R., et al. Neoangiogenesis, T-lymphocyte infiltration, and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis. JAm Coll Cardiol 2004, 43:1670-1676.
10. Coté N., Mahmut A., Bosse Y., et al. Inflammation is associated with the remodeling of calcific aortic valve disease. Inflammation 2013, 36:573-581.
11. Steiner I., Kasparova P., Kohout A., Dominik J. Bone formation in cardiac valves: a histopathological study of 128 cases. Virchows Arch 2007, 450:653-657.
12. Li C., Xu S., Gotlieb A.I. The progression of calcific aortic valve disease through injury, cell dysfunction, and disruptive biologic and physical force feedback loops. Cardiovasc Pathol 2013, 22:1-8.
13. Liu A.C., Joag V.R., Gotlieb A.I. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am J Pathol 2007, 171:1407-1418.
14. Chen J.H., Yip C.Y., Sone E.D., Simmons C.A. Identification and characterization of aortic valve mesenchymal progenitor cells with robust osteogenic calcification potential. Am J Pathol 2009, 174:1109-1119.
15. Stewart B.F., Siscovick D., Lind B.K., et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. JAm Coll Cardiol 1997, 29:630-634.
16. Nadlonek N.A., Lee J.H., Weyant M.J., Meng X., Fullerton D.A. ox-LDL induces PiT-1 expression in human aortic valve interstitial cells. JSurg Res 2013, 184:6-9.
17. Mohty D., Pibarot P., Despres J.P., et al. Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol 2008, 28:187-193.
18. Briand M., Lemieux I., Dumesnil J.G., et al. Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. JAm Coll Cardiol 2006, 47:2229-2236.
19. Capoulade R., Clavel M.A., Dumesnil J.G., et al. Impact of metabolic syndrome on progression of aortic stenosis: influence of age and statin therapy. JAm Coll Cardiol 2012, 60:216-223.
20. Miller J.D., Chu Y., Brooks R.M., et al. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. JAm Coll Cardiol 2008, 52:843-850.
21. Mahmut A., Boulanger M.C., Husseini D.E., et al. Elevated expression of Lp-PLA2 in calcific aortic valve disease: implication for valve mineralization. JAm Coll Cardiol 2014, 63:460-469.
22. Thanassoulis G., Campbell C.Y., Owens D.S., et al. Genetic associations with valvular calcification and aortic stenosis. NEngl J Med 2013, 368:503-512.
23. Kamstrup P.R., Tybjaerg-Hansen A., Nordestgaard B.G. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. JAm Coll Cardiol 2014, 63:470-477.
24. Hung M.Y., Witztum J.L., Tsimikas S. New therapeutic targets for calcific aortic valve stenosis: the lipoprotein (a), lipoprotein-associated phospholipase a, oxidized phospholipid axis. JAm Coll Cardiol 2014, 63:478-480.
25. Mahmut A., Boulanger M.C., Fournier D., et al. Lipoprotein lipase in aortic valve stenosis is associated with lipid retention and remodelling. Eur J Clin Invest 2013, 43:570-578.
26. Derbali H., Bosse Y., Cote N., et al. Increased biglycan in aortic valve stenosis leads to the overexpression of phospholipid transfer protein via Toll-like receptor 2. Am J Pathol 2010, 176:2638-2645.
27. Mathieu P., Pibarot P., Despres J.P. Metabolic syndrome: the danger signal in atherosclerosis. Vasc Health Risk Manag 2006, 2:285-302.
28. Parhami F., Basseri B., Hwang J., Tintut Y., Demer L.L. High-density lipoprotein regulates calcification of vascular cells. Circ Res 2002, 91:570-576.
29. Arsenault B.J., Dube M.P., Brodeur M.R., et al. Evaluation of links between high-density lipoprotein genetics, functionality, and aortic valve stenosis risk in humans. Arterioscler Thromb Vasc Biol 2014, 34:457-462.
30. Audet A., Cote N., Couture C., et al. Amyloid substance within stenotic aortic valves promotes mineralization. Histopathology 2012, 61:610-619.
31. Trapeaux J., Busseuil D., Shi Y., et al. Improvement of aortic valve stenosis by ApoA-I mimetic therapy is associated with decreased aortic root and valve remodelling in mice. Br J Pharmacol 2013, 169:1587-1599.
32. Bosse Y., Miqdad A., Fournier D., et al. Refining molecular pathways leading to calcific aortic valve stenosis by studying gene expression profile of normal and calcified stenotic human aortic valves. Circ Cardiovasc Genet 2009, 2:489-498.
33. Yoshioka M., Yuasa S., Matsumura K., et al. Chondromodulin-I maintains cardiac valvular function by preventing angiogenesis. Nat Med 2006, 12:1151-1159.
34. Perrotta I., Russo E., Camastra C., et al. New evidence for a critical role of elastin in calcification of native heart valves: immunohistochemical and ultrastructural study with literature review. Histopathology 2011, 59:504-513.
35. Galeone A., Paparella D., Colucci S., Grano M., Brunetti G. The role of TNF- and TNF superfamily members in the pathogenesis of calcific aortic valvular disease. ScientificWorldJournal 2013, 2013:875363.
36. Tintut Y., Parhami F., Bostrom K., Jackson S.M., Demer L.L. cAMP stimulates osteoblast-like differentiation of calcifying vascular cells. Potential signaling pathway for vascular calcification. JBiol Chem 1998, 273:7547-7553.
37. Lee H.L., Woo K.M., Ryoo H.M., Baek J.H. Tumor necrosis factor-alpha increases alkaline phosphatase expression in vascular smooth muscle cells via MSX2 induction. Biochem Biophys Res Commun 2010, 391:1087-1092.
38. Al-Aly Z., Shao J.S., Lai C.F., et al. Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/- mice. Arterioscler Thromb Vasc Biol 2007, 27:2589-2596.
39. Galeone A., Brunetti G., Oranger A., et al. Aortic valvular interstitial cells apoptosis and calcification are mediated by TNF-related apoptosis-inducing ligand. Int J Cardiol 2013, 169:296-304.
40. Isoda K., Matsuki T., Kondo H., Iwakura Y., Ohsuzu F. Deficiency of interleukin-1 receptor antagonist induces aortic valve disease in BALB/c mice. Arterioscler Thromb Vasc Biol 2010, 30:708-715.
41. Song R., Zeng Q., Ao L., et al. Biglycan induces the expression of osteogenic factors in human aortic valve interstitial cells via Toll-like receptor-2. Arterioscler Thromb Vasc Biol 2012, 32:2711-2720.
42. El Husseini D., Boulanger M.C., Mahmut A., et al. P2Y2 receptor represses IL-6 expression by valve intertstitial cells through Akt: implication for calcific aortic valve disease. JMol Cell Cardiol 2014, 72C:146-156.
43. Mahler G.J., Farrar E.J., Butcher J.T. Inflammatory cytokines promote mesenchymal transformation in embryonic and adult valve endothelial cells. Arterioscler Thromb Vasc Biol 2013, 33:121-130.
44. Capoulade R., Clavel M.A., Mathieu P., et al. Impact of hypertension and renin-angiotensin system inhibitors in aortic stenosis. Eur J Clin Invest 2013, 43:1262-1272.
45. Mathieu P., Poirier P., Pibarot P., Lemieux I., Despres J.P. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension 2009, 53:577-584.
46. O'Brien K.D., Probstfield J.L., Caulfield M.T., et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med 2005, 165:858-862.
47. Cote N., Pibarot P., Pepin A., et al. Oxidized low-density lipoprotein, angiotensin II and increased waist cirumference are associated with valve inflammation in prehypertensive patients with aortic stenosis. Int J Cardiol 2010, 145:444-449.
48. Fujisaka T., Hoshiga M., Hotchi J., et al. Angiotensin II promotes aortic valve thickening independent of elevated blood pressure in apolipoprotein-E deficient mice. Atherosclerosis 2013, 226:82-87.
49. O'Brien K.D., Shavelle D.M., Caulfield M.T., et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 2002, 106:2224-2230.
50. Helske S., Lindstedt K.A., Laine M., et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. JAm Coll Cardiol 2004, 44:1859-1866.
51. Rosenhek R., Rader F., Loho N., et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004, 110:1291-1295.
52. Cote N., Couture C., Pibarot P., Despres J.P., Mathieu P. Angiotensin receptor blockers are associated with a lower remodelling score of stenotic aortic valves. Eur J Clin Invest 2011, 41:1172-1179.
53. Cote N., Mahmut A., Fournier D., et al. Angiotensin receptor blockers are associated with reduced fibrosis and interleukin-6 expression in calcific aortic valve disease. Pathobiology 2014, 81:15-24.
54. Arishiro K., Hoshiga M., Negoro N., et al. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. JAm Coll Cardiol 2007, 49:1482-1489.
55. Ketteler M., Bongartz P., Westenfeld R., et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003, 361:827-833.
56. Doyon M., Mathieu P., Moreau P. Decreased expression of gamma-carboxylase in diabetes-associated arterial stiffness: impact on matrix Gla protein. Cardiovasc Res 2013, 97:331-338.
57. Linefsky J.P., O'Brien K.D., Katz R., et al. Association of serum phosphate levels with aortic valve sclerosis and annular calcification: the cardiovascular health study. JAm Coll Cardiol 2011, 58:291-297.
58. Mathieu P., Voisine P., Pepin A., et al. Calcification of human valve interstitial cells is dependent on alkaline phosphatase activity. JHeart Valve Dis 2005, 14:353-357.
59. El Husseini D., Boulanger M.C., Fournier D., et al. High expression of the Pi-transporter SLC20A1/Pit1 in calcific aortic valve disease promotes mineralization through regulation of Akt-1. PLoS One 2013, 8:e53393.
60. CÔté N., El Husseini D., Pépin A., et al. ATP acts as a survival signal and prevents the mineralization of aortic valve. JMol Cell Cardiol 2012, 52:1191-1202.
61. Okawa A., Nakamura I., Goto S., et al. Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet 1998, 19:271-273.
62. Mathieu P. Pharmacology of ectonucleotidases: relevance for the treatment of cardiovascular disorders. Eur J Pharmacol 2012, 696:1-4.
63. Bouchareb R., Boulanger M.C., Fournier D., et al. Mechanical strain induces the production of spheroid mineralized microparticles in the aortic valve through a RhoA/ROCK-dependent mechanism. JMol Cell Cardiol 2014, 67:49-59.
64. CÔté N1 El Husseini D., Pépin A., et al. Inhibition of ectonucleotidase with ARL67156 prevents the development of calcific aortic valve disease in warfarin-treated rats. Eur J Pharmacol 2012, 689:139-146.
65. Mohler E.R., Gannon F., Reynolds C., et al. Bone formation and inflammation in cardiac valves. Circulation 2001, 103:1522-1528.
66. Garg V., Muth A.N., Ransom J.F., et al. Mutations in NOTCH1 cause aortic valve disease. Nature 2005, 437:270-274.
67. Guruharsha K.G., Kankel M.W., Artavanis-Tsakonas S. The Notch signalling system: recent insights into the complexity of a conserved pathway. Nat Rev Genet 2012, 13:654-666.
68. Nigam V., Srivastava D. Notch1 represses osteogenic pathways in aortic valve cells. JMol Cell Cardiol 2009, 47:828-834.
69. Nus M., MacGrogan D., Martinez-Poveda B., et al. Diet-induced aortic valve disease in mice haploinsufficient for the Notch pathway effector RBPJK/CSL. Arterioscler Thromb Vasc Biol 2011, 31:1580-1588.
70. Tkatchenko T.V., Moreno-Rodriguez R.A., Conway S.J., et al. Lack of periostin leads to suppression of Notch1 signaling and calcific aortic valve disease. Physiol Genomics 2009, 39:160-168.
71. Ducharme V., Guauque-Olarte S., Gaudreault N., et al. NOTCH1 genetic variants in patients with tricuspid calcific aortic valve stenosis. JHeart Valve Dis 2013, 22:142-149.
72. Caira F.C., Stock S.R., Gleason T.G., et al. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. JAm Coll Cardiol 2006, 47:1707-1712.
73. Komiya Y., Habas R. Wnt signal transduction pathways. Organogenesis 2008, 4:68-75.
74. Zhang R., Oyajobi B.O., Harris S.E., et al. Wnt/beta-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts. Bone 2013, 52:145-156.
75. Deregowski V., Gazzerro E., Priest L., Rydziel S., Canalis E. Notch 1 overexpression inhibits osteoblastogenesis by suppressing Wnt/beta-catenin but not bone morphogenetic protein signaling. JBiol Chem 2006, 281:6203-6210.
76. Bernstein B.E., Birney E., Dunham I., et al. An integrated encyclopedia of DNA elements in the human genome. Nature 2012, 489:57-74.
77. Zhang M., Liu X., Zhang X., et al. MicroRNA-30b is a multifunctional regulator of aortic valve interstitial cells. JThorac Cardiovasc Surg 2014, 147:1073-1080.e2.
78. Yanagawa B., Lovren F., Pan Y., et al. miRNA-141 is a novel regulator of BMP-2-mediated calcification in aortic stenosis. JThorac Cardiovasc Surg 2012, 144:256-262.
79. Hutcheson J.D., Chen J., Sewell-Loftin M.K., et al. Cadherin-11 regulates cell-cell tension necessary for calcific nodule formation by valvular myofibroblasts. Arterioscler Thromb Vasc Biol 2013, 33:114-120.
80. Chen J.H., Chen W.L., Sider K.L., Yip C.Y., Simmons C.A. Beta-catenin mediates mechanically regulated, transforming growth factor-beta1-induced myofibroblast differentiation of aortic valve interstitial cells. Arterioscler Thromb Vasc Biol 2011, 31:590-597.
81. Hutcheson J.D., Ryzhova L.M., Setola V., Merryman W.D. 5-HT(2B) antagonism arrests non-canonical TGF-beta1-induced valvular myofibroblast differentiation. JMol Cell Cardiol 2012, 53:707-714.
82. Jaffre F., Bonnin P., Callebert J., et al. Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. Circ Res 2009, 104:113-123.
83. Simmons C.A., Grant G.R., Manduchi E., Davies P.F. Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. Circ Res 2005, 96:792-799.
84. El-Hamamsy I., Balachandran K., Yacoub M.H., et al. Endothelium-dependent regulation of the mechanical properties of aortic valve cusps. JAm Coll Cardiol 2009, 53:1448-1455.
85. Bosse K., Hans C.P., Zhao N., et al. Endothelial nitric oxide signaling regulates Notch1 in aortic valve disease. JMol Cell Cardiol 2013, 60:27-35.
86. Rajamannan N.M. Oxidative-mechanical stress signals stem cell niche mediated Lrp5 osteogenesis in eNOS(-/-) null mice. JCell Biochem 2012, 113:1623-1634.
87. Balachandran K., Sucosky P., Jo H., Yoganathan A.P. Elevated cyclic stretch induces aortic valve calcification in a bone morphogenic protein-dependent manner. Am J Pathol 2010, 177:49-57.
88. Tohno Y., Tohno S., Minami T., et al. Age-related change of mineral content in the human thoracic aorta and in the human cerebral artery. Biol Trace Elem Res 1996, 54:23-31.
89. Mohty D., Pibarot P., Despres J.P., et al. Age-related differences in the pathogenesis of calcific aortic stenosis: the potential role of resistin. Int J Cardiol 2010, 142:126-132.
90. Paramsothy P., Katz R., Owens D.S., et al. Age-modification of lipoprotein, lipid, and lipoprotein ratio-associated risk for coronary artery calcium (from the Multi-Ethnic Study of Atherosclerosis [MESA]). Am J Cardiol 2010, 105:352-358.
91. Reilly M.P., Lehrke M., Wolfe M.L., et al. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005, 111:932-939.
92. Carter S., Miard S., Roy-Bellavance C., et al. Sirt1 inhibits resistin expression in aortic stenosis. PLoS One 2012, 7:e35110.
93. Mouchiroud L., Houtkooper R.H., Moullan N., et al. The NAD(+)/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell 2013, 154:430-441.